VPS35 — важный белок, играющий многофункциональную роль в различных биологических процессах. Он является ключевым компонентом ретромерного комплекса, участвующего в рециркуляции белков из эндосом в транссеть Гольджи (ТСГ) и плазматическую мембрану. Помимо своей роли в качестве компонента ретромерного комплекса, VPS35 взаимодействует со многими белками и регулирует митохондриальный гомеостаз, митохондриальную динамику (слияние и деление) и другие важные процессы в различных клеточных компартментах. В контексте болезни Паркинсона (БП) существуют убедительные доказательства того, что мутации VPS35, в частности [D620N], оказывают значительное влияние на нормальное функционирование ретромера, митохондриальную дисфункцию и ухудшение здоровья и выживаемости нейронов. В этом обзоре мы кратко рассмотрим структуру и функции ретромерного комплекса, роль VPS35 в митохондриях и, наконец, проанализируем физические и функциональные взаимодействия этого белка с важными для БП белками, связанными с митохондриями.
Бунеева О.А., Медведев А.Е. (2026) Белок VPS35 и роль его нарушений в митохондриальной дисфункции при болезни Паркинсона. Биомедицинская химия, 72(1), 5-20.
Бунеева О.А. и др. Белок VPS35 и роль его нарушений в митохондриальной дисфункции при болезни Паркинсона // Биомедицинская химия. - 2026. - Т. 72. -N 1. - С. 5-20.
Бунеева О.А. и др., "Белок VPS35 и роль его нарушений в митохондриальной дисфункции при болезни Паркинсона." Биомедицинская химия 72.1 (2026): 5-20.
Бунеева, О. А., Медведев, А. Е. (2026). Белок VPS35 и роль его нарушений в митохондриальной дисфункции при болезни Паркинсона. Биомедицинская химия, 72(1), 5-20.
Список литературы
Costa H.N., Esteves A.R., Empadinhas N., Cardoso S.M. (2022) Parkinson’s disease: a multisystem disorder. Neurosci. Bull., 39(1), 113. CrossRef Scholar google search
Ben-Shlomo Y., Darweesh S., Llibre-Guerra J., Marras C., San Luciano M., Tanner C. (2024) The epidemiology of Parkinson’s disease. Lancet, 403(10423), 283–292. CrossRef Scholar google search
GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease study 2016. Lancet Neurol., 18(5), 459–480. CrossRef Scholar google search
Su D., Cui Y., He C., Yin P., Bai R., Zhu J., Lam J.S.T., Zhang J., Yan R., Zheng X., Wu J., Zhao D., Wang A., Zhou M., Feng T. (2025) Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease study 2021. BMJ, 388, e080952. CrossRef Scholar google search
Armstrong M.J., Okun M.S. (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA, 323(6), 548–560. CrossRef Scholar google search
Baggett D., Olson A., Parmar M.S. (2024) Novel approaches targeting α-synuclein for Parkinson’s disease: current progress and future directions for the disease-modifying therapies. Brain Disord., 16, 100163. CrossRef Scholar google search
Oliveira L.M.A., Gasser T., Edwards R., Zweckstetter M., Melki R., Stefanis L., Lashuel H.A., Sulzer D., Vekrellis K., Halliday G.M., Tomlinson J.J., Schlossmacher M., Jensen P.H., Schulze-Hentrich J., Riess O., Hirst W.D., El-Agnaf O., Mollenhauer B., Lansbury P., Outeiro T.F. (2021) Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. NPJ Parkinsons Dis., 7(1), 65. CrossRef Scholar google search
Morris H.R., Spillantini M.G., Sue C.M., Williams-Gray C.H. (2024) The pathogenesis of Parkinson’s disease. Lancet, 403(10423), 293–304. CrossRef Scholar google search
Sulzer D., Edwards R.H. (2019) The physiological role of α-synuclein and its relationship to Parkinson’s disease. J. Neurochem., 150(5), 475–486. CrossRef Scholar google search
Kouli A., Torsney K.M., Kuan W.-L. (2018) Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Parkinson’s Disease: Pathogenesis and Clinical Aspects (Stoker T.B., Greenland J.C., eds.) Codon Publications, Brisbane (AU), pp. 3–26. Scholar google search
Adler C.H., Beach T.G. (2016) Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov. Disord., 31(8), 1114–1119. CrossRef Scholar google search
Marras C., Chaudhuri K.R. (2016) Nonmotor features of Parkinson’s disease subtypes. Mov. Disord., 31(8), 1095–1102. CrossRef Scholar google search
Langston J.W., Irwin I., Langston E.B., Forno L.S. (1984) 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett., 48(1), 87–92. CrossRef Scholar google search
Бунеева О.А., Медведев А.Е. (2011) Нарушение функций митохондрий при болезни Паркинсона. Биомедицинская химия, 57(3), 246–281. CrossRef Scholar google search
Bose A., Beal M.F. (2016) Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem., 139(Suppl 1), 216–231. CrossRef Scholar google search
Бунеева О.А., Медведева М.В., Копылов А.Т., Медведев А.Е. (2019) Убиквитиновый субпротеом митохондрий мозга и его изменения при экспериментальном паркинсонизме и действии нейропротекторов. Биохимия, 84(11), 1683–1700. CrossRef Scholar google search
Бунеева О.А., Медведев А.Е. (2006) Убиквитин- протеинлигаза паркин: роль в развитии болезни Паркинсона. Биохимия, 71(8), 1050–1061. CrossRef Scholar google search
Zhao Y., Lin M., Zhai F., Chen J., Jin X. (2024) Exploring the role of ubiquitin-proteasome system in the pathogenesis of Parkinson’s disease. Pharmaceuticals, 17(6), 782. CrossRef Scholar google search
Buneeva O., Medvedev A. (2022) Atypical ubiquitination and Parkinson’s disease. Int. J. Mol. Sci., 23(7), 3705. CrossRef Scholar google search
Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., di Iorio G., Golbe L.I., Nussbaum R.L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276(5321), 2045–2047. CrossRef Scholar google search
Singleton A.B., Farrer M.J., Bonifati V. (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov. Disord., 28(1), 14–23. CrossRef Scholar google search
Lunati A., Lesage S., Brice A. (2018) The genetic landscape of Parkinson’s disease. Rev. Neurol. (Paris), 174(9), 628–643. CrossRef Scholar google search
Domingo A., Klein C. (2018) Genetics of Parkinson disease. Handb. Clin. Neurol., 147, 211–227. CrossRef Scholar google search
Kim C.Y., Alcalay R.N. (2017) Genetic forms of Parkinson’s disease. Semin. Neurol., 37(2), 135–146. CrossRef Scholar google search
Cherian A., Divya K.P., Vijayaraghavan A. (2023) Parkinson’s disease — genetic cause. Curr. Opin. Neurol., 36(4), 292–301. CrossRef Scholar google search
Ye H., Robak L.A., Yu M., Cykowski M., Shulman J.M. (2023) Genetics and pathogenesis of Parkinson’s syndrome. Annu. Rev. Pathol., 18, 95–121. CrossRef Scholar google search
Nussbaum R.L. (2017) The identification of alpha-synuclein as the first Parkinson disease gene. J. Parkinsons Dis., 7(s1), S43–S49. CrossRef Scholar google search
Vilariño-Güell C., Wider C., Ross O.A., Dachsel J.C., Kachergus J.M., Lincoln S.J., Soto-Ortolaza A.I., Cobb S.A., Wilhoite G.J., Bacon J.A., Behrouz B., Melrose H.L., Hentati E., Puschmann A., Evans D.M., Conibear E., Wasserman W.W., Aasly J.O., Burkhard P.R., Djaldetti R., Ghika J., Hentati F., Krygowska-Wajs A., Lynch T., Melamed E., Rajput A., Rajput A.H., Solida A., Wu R.-M., Uitti R.J., Wszolek Z.K., Vingerhoets F., Farrer M.J. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet., 89, 162–167. CrossRef Scholar google search
Zimprich A., Benet-Pagès A., Struhal W., Graf E., Eck S.H., Offman M.N., Haubenberger D., Spielberger S., Schulte E.C., Lichtner P., Rossle S.C., Klopp N., Wolf E., Seppi K., Pirker W., Presslauer S., Mollenhauer B., Katzenschlager R., Foki T., Hotzy C., Reinthaler E., Harutyunyan A., Kralovics R., Peters A., Zimprich F., Brücke T., Poewe W., Auff E., Trenkwalder C., Rost B., Ransmayr G., Winkelmann J., Meitinger T., Strom T.M. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet., 89, 168–175. CrossRef Scholar google search
Rahman A.A., Morrison B.E. (2019) Contributions of VPS35 mutations to Parkinson’s disease. Neuroscience, 401, 1–10. CrossRef Scholar google search
Sassone J., Reale C., Dati G., Regoni M., Pellecchia M.T., Garavaglia B. (2021) The role of VPS35 in the pathobiology of Parkinson’s disease. Cell. Mol. Neurobiol., 41(2), 199–227. CrossRef Scholar google search
Sheerin U.-M., Charlesworth G., Bras J., Guerreiro R., Bhatia K., Foltynie T., Limousin P., Silveira-Moriyama L., Lees A., Wood N. (2012) Screening for VPS35 mutations in Parkinson’s disease. Neurobiol. Aging, 33(4), 838.e1–5. CrossRef Scholar google search
Wider C., Skipper L., Solida A., Brown L., Farrer M., Dickson D., Wszolek Z.K., Vingerhoets F.J.G. (2008) Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat. Disord., 14(6), 465–470. CrossRef Scholar google search
Chen Y.-F., Chang Y.-Y., Lan M.-Y., Chen P.-L., Lin C.-H. (2017) Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review. BMC Neurol., 17(1), 191. CrossRef Scholar google search
Kumar K.R., Weissbach A., Heldmann M., Kasten M., Tunc S., Sue C.M., Svetel M., Kostić V.S., Segura-Aguilar J., Ramirez A., Simon D.K., Vieregge P., Münte T.F., Hagenah J., Klein C., Lohmann K. (2012) Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol., 69(10), 1360–1364. CrossRef Scholar google search
Ando M., Funayama M., Li Y., Kashihara K., Murakami Y., Ishizu N., Toyoda C., Noguchi K., Hashimoto T., Nakano N., Sasaki R., Kokubo Y., Kuzuhara S., Ogaki K., Yamashita C., Yoshino H., Hatano T., Tomiyama H., Hattori N. (2012) VPS35 mutation in Japanese patients with typical Parkinson’s disease. Mov. Disord., 27(11), 1413–1417. CrossRef Scholar google search
Sharma M., Ioannidis J.P.A., Aasly J.O., Annesi G., Brice A., Bertram L., Bozi M., Barcikowska M., Crosiers D., Clarke C.E., Facheris M.F., Farrer M., Garraux G., Gispert S., Auburger G., Vilariño-Güell C., Hadjigeorgiou G.M., Hicks A.A., Hattori N., Jeon B.S., Jamrozik Z., Krygowska-Wajs A., Lesage S., Lill C.M., Lin J.J., Lynch T., Lichtner P., Lang A.E., Libioulle C., Murata M., Mok V., Jasinska-Myga B., Mellick G.D., Morrison K.E., Meitnger T., Zimprich A., Opala G., Pramstaller P.P., Pichler I., Park S.S., Quattrone A., Rogaeva E., Ross O.A., Stefanis L., Stockton J.D., Satake W., Silburn P.A., Strom T.M., Theuns J., Tan E.K., Toda T., Tomiyama H., Uitti R.J., van Broeckhoven C., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Yomono H.S., Yueh K.C., Zhao Y., Gasser T., Maraganore D., Krüger R. (2012) A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J. Med. Genet., 49(11), 721–726. CrossRef Scholar google search
Chen X., Kordich J.K., Williams E.T., Levine N., Cole-Strauss A., Marshall L., Labrie V., Ma J., Lipton J.W., Moore D.J. (2019) Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA, 116(12), 5765–5774. CrossRef Scholar google search
Tsika E., Glauser L., Moser R., Fiser A., Daniel G., Sheerin U.-M., Lees A., Troncoso J.C., Lewis P.A., Bandopadhyay R., Schneider B.L., Moore D.J. (2014) Parkinson’s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet., 23(17), 4621–4638. CrossRef Scholar google search
Paravicini G., Horazdovsky B.F., Emr S.D. (1992) Alternative pathways for the sorting of soluble vacuolar proteins in yeast: a vps35 null mutant missorts and secretes only a subset of vacuolar hydrolases. Mol. Biol. Cell, 3(4), 415–427. CrossRef Scholar google search
Seaman M.N., McCaffery J.M., Emr S.D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J. Cell Biol., 142(3), 665–681. CrossRef Scholar google search
Hierro A., Rojas A.L., Rojas R., Murthy N., Effantin G., Kajava A.V., Steven A.C., Bonifacino J.S., Hurley J.H. (2007) Functional architecture of the retromer cargo-recognition complex. Nature, 449(7165), 1063–1067. CrossRef Scholar google search
Gokool S., Tattersall D., Reddy J.V., Seaman M.N.J. (2007) Identification of a conserved motif required for Vps35p/Vps26p interaction and assembly of the retromer complex. Biochem. J., 408(2), 287–295. CrossRef Scholar google search
Collins B.M., Norwood S.J., Kerr M.C., Mahony D., Seaman M.N.J., Teasdale R.D., Owen D.J. (2008) Structure of Vps26B and mapping of its interaction with the retromer protein complex. Traffic, 9(3), 366–379. CrossRef Scholar google search
Collins B.M., Skinner C.F., Watson P.J., Seaman M.N.J., Owen D.J. (2005) Vps29 has a phosphoesterase fold that acts as a protein interaction scaffold for retromer assembly. Nat. Struct. Mol. Biol., 12(7), 594–602. CrossRef Scholar google search
Shi H., Rojas R., Bonifacino J.S., Hurley J.H. (2006) The retromer subunit Vps26 has an arrestin fold and binds Vps35 through its C-terminal domain. Nat. Struct. Mol. Biol., 13(6), 540–548. CrossRef Scholar google search
Lucas M., Gershlick D.C., Vidaurrazaga A., Rojas A.L., Bonifacino J.S., Hierro A. (2016) Structural mechanism for cargo recognition by the retromer complex. Cell, 167(6), 1623–1635.e14. CrossRef Scholar google search
Kim E., Lee Y., Lee H.-J., Kim J.S., Song B.-S., Huh J.-W., Lee S.-R., Kim S.-U., Kim S.-H., Hong Y., Shim I., Chang K.-T. (2010) Implication of mouse Vps26b-Vps29-Vps35 retromer complex in sortilin trafficking. Biochem. Biophys. Res. Commun., 403(2), 167–171. CrossRef Scholar google search
Bugarcic A., Zhe Y., Kerr M.C., Griffin J., Collins B.M., Teasdale R.D. (2011) Vps26A and Vps26B subunits define distinct retromer complexes. Traffic, 12(12), 1759–1773. CrossRef Scholar google search
Bugarcic A., Vetter I., Chalmers S., Kinna G., Collins B.M., Teasdale R.D. (2015) Vps26B-retromer negatively regulates plasma membrane resensitization of PAR-2. Cell Biol. Int., 39(11), 1299–1306. CrossRef Scholar google search
Kerr M.C., Bennetts J.S., Simpson F., Thomas E.C., Flegg C., Gleeson P.A., Wicking C., Teasdale R.D. (2005) A novel mammalian retromer component, Vps26B. Traffic, 6(11), 991–1001. CrossRef Scholar google search
Gallon M., Cullen P.J. (2015) Retromer and sorting nexins in endosomal sorting. Biochem. Soc. Trans., 43(1), 33–47. CrossRef Scholar google search
Cullen P.J., Korswagen H.C. (2012) Sorting nexins provide diversity for retromer-dependent trafficking events. Nat. Cell Biol., 14(1), 29–37. CrossRef Scholar google search
Seaman M.N.J. (2021) The retromer complex: from genesis to revelations. Trends Biochem. Sci., 46(7), 608–620. CrossRef Scholar google search
Wang J., Fedoseienko A., Chen B., Burstein E., Jia D., Billadeau D.D. (2018) Endosomal receptor trafficking: retromer and beyond. Traffic, 19(8), 578–590. CrossRef Scholar google search
Carosi J.M., Denton D., Kumar S., Sargeant T.J. (2023) Receptor recycling by retromer. Mol. Cell. Biol., 43(7), 317–334. CrossRef Scholar google search
Cui Y., Yang Z., Teasdale R.D. (2018) The functional roles of retromer in Parkinson’s disease. FEBS Lett., 592(7), 1096–1112. CrossRef Scholar google search
Fokin A.I., Gautreau A.M. (2021) Assembly and activity of the WASH molecular machine: distinctive features at the crossroads of the actin and microtubule cytoskeletons. Front. Cell Dev. Biol., 9, 658865. CrossRef Scholar google search
Ryder P.V., Vistein R., Gokhale A., Seaman M.N., Puthenveedu M.A., Faundez V. (2013) The WASH complex, an endosomal Arp2/3 activator, interacts with the Hermansky-Pudlak syndrome complex BLOC-1 and its cargo phosphatidylinositol-4-kinase type IIα. Mol. Biol. Cell, 24(14), 2269–2284. CrossRef Scholar google search
Romano-Moreno M., Astorga-Simyn E.N., Rojas A.L., Hierro A. (2024) Retromer-mediated recruitment of the WASH complex involves discrete interactions between VPS35, VPS29, and FAM21. Protein Sci., 33(5), e4980. CrossRef Scholar google search
Dostál V., Humhalová T., Beránková P., Pácalt O., Libusová L. (2023) SWIP mediates retromer-independent membrane recruitment of the WASH complex. Traffic, 24(5), 216–230. CrossRef Scholar google search
Zavodszky E., Seaman M.N.J., Moreau K., Jimenez-Sanchez M., Breusegem S.Y., Harbour M.E., Rubinsztein D.C. (2014) Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy. Nat. Commun., 5, 3828. CrossRef Scholar google search
Follett J., Norwood S.J., Hamilton N.A., Mohan M., Kovtun O., Tay S., Zhe Y., Wood S.A., Mellick G.D., Silburn P.A., Collins B.M., Bugarcic A., Teasdale R.D. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic, 15(2), 230–244. CrossRef Scholar google search
Fan X., Xie Y., Cao S., Zhu L., Wang X. (2025) VPS35-retromer: multifunctional roles in various biological processes — a focus on neurodegenerative diseases and cancer. J. Inflamm. Res., 18, 4665–4680. CrossRef Scholar google search
Baños-Mateos S., Rojas A.L., Hierro A. (2019) VPS29, a tweak tool of endosomal recycling. Curr. Opin. Cell Biol., 59, 81–87. CrossRef Scholar google search
Shannon B., Soto-Ortolaza A., Rayaprolu S., Cannon H.D., Labbé C., Benitez Bruno.A., Choi J., Lynch T., Boczarska-Jedynak M., Opala G., Krygowska-Wajs A., Barcikowska M., van Gerpen J.A., Uitti R.J., Springer W., Cruchaga C., Wszolek Z.K., Ross O.A. (2014) Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson’s disease. Neurobiol. Aging, 35(8), 1958.e1–e2. CrossRef Scholar google search
Seong J.B., Kim Y.-H., Huh J.-W., Lee Y. (2023) VPS26b plays a protective role against MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells. IBRO Neurosci. Rep., 15(Suppl 1), S203. CrossRef Scholar google search
Buneeva O., Kopylov A., Kapitsa I., Ivanova E., Zgoda V., Medvedev A. (2018) The effect of neurotoxin MPTP and neuroprotector isatin on the profile of ubiquitinated brain mitochondrial proteins. Cells, 7(8), 91. CrossRef Scholar google search
Buneeva O., Fedchenko V., Kopylov A., Medvedev A. (2020) Mitochondrial dysfunction in Parkinson’s disease: focus on mitochondrial DNA. Biomedicines, 8(12), 591. CrossRef Scholar google search
Hattori N., Sato S. (2024) Mitochondrial dysfunction in Parkinson’s disease. J. Neural Transm. (Vienna), 131(12), 1415–1428. CrossRef Scholar google search
Moon H.E., Paek S.H. (2015) Mitochondrial dysfunction in Parkinson’s disease. Exp. Neurobiol., 24(2), 103–116. CrossRef Scholar google search
Ammal Kaidery N., Thomas B. (2018) Current perspective of mitochondrial biology in Parkinson’s disease. Neurochem. Int., 117, 91–113. CrossRef Scholar google search
Rey F., Ottolenghi S., Zuccotti G.V., Samaja M., Carelli S. (2022) Mitochondrial dysfunctions in neurodegenerative diseases: role in disease pathogenesis, strategies for analysis and therapeutic prospects. Neural Regen. Res., 17(4), 754–758. CrossRef Scholar google search
Rossi A., Pizzo P., Filadi R. (2019) Calcium, mitochondria and cell metabolism: a functional triangle in bioenergetics. Biochim. Biophys. Acta Mol. Cell Res., 1866(7), 1068–1078. CrossRef Scholar google search
Tait S.W.G., Green D.R. (2012) Mitochondria and cell signalling. J. Cell Sci., 125(Pt 4), 807–815. CrossRef Scholar google search
Chakrabarty R.P., Chandel N.S. (2022) Beyond ATP, new roles of mitochondria. Biochemist (London), 44(4), 2–8. CrossRef Scholar google search
Spinelli J.B., Haigis M.C. (2018) The multifaceted contributions of mitochondria to cellular metabolism. Nat. Cell Biol., 20(7), 745–754. CrossRef Scholar google search
Buneeva O., Medvedev A. (2025) Monoamine oxidase inhibitors in toxic models of Parkinsonism. Int. J. Mol. Sci., 26(3), 1248. CrossRef Scholar google search
Glinka Y.Y., Youdim M.B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol., 292(3–4), 329–332. CrossRef Scholar google search
Subhan I., Siddique Y.H. (2024) Effect of rotenone on the neurodegeneration among different models. Curr. Drug Targets, 25(8), 530–542. CrossRef Scholar google search
Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.-H., Lund S., Na H.-M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., Greenamyre J.T. (2006) Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis., 22(2), 404–420. CrossRef Scholar google search
Elmorsy E., Al-Ghafari A., Al Doghaither H., Hashish S., Salama M., Mudyanselage A.W., James L., Carter W.G. (2023) Differential effects of paraquat, rotenone, and MPTP on cellular bioenergetics of undifferentiated and differentiated human neuroblastoma cells. Brain Sci., 13(12), 1717. CrossRef Scholar google search
Varešlija D., Tipton K.F., Davey G.P., McDonald A.G. (2020) 6-Hydroxydopamine: a far from simple neurotoxin. J. Neural Transm. (Vienna), 127(2), 213–230. CrossRef Scholar google search
Bi F., Li F., Huang C., Zhou H. (2013) Pathogenic mutation in VPS35 impairs its protection against MPP+ cytotoxicity. Int. J. Biol. Sci., 9(2), 149–155. CrossRef Scholar google search
Hanss Z., Larsen S.B., Antony P., Mencke P., Massart F., Jarazo J., Schwamborn J.C., Barbuti P.A., Mellick G.D., Krüger R. (2021) Mitochondrial and clearance impairment in p.D620N VPS35 patient-derived neurons. Mov. Disord., 36(3), 704–715. CrossRef Scholar google search
Bertholet A.M., Delerue T., Millet A.M., Moulis M.F., David C., Daloyau M., Arnauné-Pelloquin L., Davezac N., Mils V., Miquel M.C., Rojo M., Belenguer P. (2016) Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity. Neurobiol. Dis., 90, 3–19. CrossRef Scholar google search
Yang D., Ying J., Wang X., Zhao T., Yoon S., Fang Y., Zheng Q., Liu X., Yu W., Hua F. (2021) Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease. Front. Neurosci., 15, 654785. CrossRef Scholar google search
Pellegrini L., Wetzel A., Granny S., Heaton G., Harvey K. (2016) Back to the tubule: microtubule dynamics in Parkinson’s disease. Cell. Mol. Life Sci., 74(3), 409–434. CrossRef Scholar google search
Yapa N.M.B., Lisnyak V., Reljic B., Ryan M.T. (2021) Mitochondrial dynamics in health and disease. FEBS Lett., 595(8),1184–1204. CrossRef Scholar google search
Grel H., Woznica D., Ratajczak K., Kalwarczyk E., Anchimowicz J., Switlik W., Olejnik P., Zielonka P., Stobiecka M., Jakiela S. (2023) Mitochondrial dynamics in neurodegenerative diseases: unraveling the role of fusion and fission processes. Int. J. Mol. Sci., 24(17), 13033. CrossRef Scholar google search
Guan D., Liang C., Zheng D., Liu S., Luo J., Cai Z., Zhang H., Chen J. (2025) The role of mitochondrial remodeling in neurodegenerative diseases. Neurochem. Int., 183, 105927. CrossRef Scholar google search
Braschi E., Goyon V., Zunino R., Mohanty A., Xu L., McBride H.M. (2010) Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr. Biol., 20(14), 1310–1315. CrossRef Scholar google search
Soubannier V., McLelland G.-L., Zunino R., Braschi E., Rippstein P., Fon E.A., McBride H.M. (2012) A vesicular transport pathway shuttles cargo from mitochondria to lysosomes. Curr. Biol., 22(2), 135–141. CrossRef Scholar google search
Sugiura A., McLelland G., Fon E.A., McBride H.M. (2014) A new pathway for mitochondrial quality control: mitochondrial-derived vesicles. EMBO J., 33(19), 2142–2156. CrossRef Scholar google search
Koyano F., Yamano K., Kosako H., Kimura Y., Kimura M., Fujiki Y., Tanaka K., Matsuda N. (2019) Parkin-mediated ubiquitylation redistributes MITOL/March5 from mitochondria to peroxisomes. EMBO Rep., 20(12), e47728. CrossRef Scholar google search
Wang W., Wang X., Fujioka H., Hoppel C., Whone A.L., Caldwell M.A., Cullen P.J., Liu J., Zhu X. (2016) Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat. Med., 22(1), 54–63. CrossRef Scholar google search
Lu B. (2009) Mitochondrial dynamics and neurodegeneration. Curr. Neurol. Neurosci. Rep., 9(3), 212–219. CrossRef Scholar google search
Itoh K., Nakamura K., Iijima M., Sesaki H. (2013) Mitochondrial dynamics in neurodegeneration. Trends Cell Biol., 23(2), 64–71. CrossRef Scholar google search
Smirnova E., Griparic L., Shurland D.-L., van der Bliek A.M. (2001) Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol. Biol. Cell, 12(8), 2245–2256. CrossRef Scholar google search
Song Z., Ghochani M., McCaffery J.M., Frey T.G., Chan D.C. (2009) Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol. Biol. Cell, 20(15), 3525–3532. CrossRef Scholar google search
Tang F.-L., Liu W., Hu J.-X., Erion J.R., Ye J., Mei L., Xiong W.-C. (2015) VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep., 12(10), 1631–1643. CrossRef Scholar google search
Wang W., Ma X., Zhou L., Liu J., Zhu X. (2017) A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson’s disease model. Hum. Mol. Genet., 26(4), 781–789. CrossRef Scholar google search
Wang X.-L., Feng S.-T., Wang Y.-T., Yuan Y.-H., Li Z.-P., Chen N.-H., Wang Z.-Z., Zhang Y. (2022) Mitophagy, a form of selective autophagy, plays an essential role in mitochondrial dynamics of Parkinson’s disease. Cell. Mol. Neurobiol., 42 (5), 1321–1339. CrossRef Scholar google search
Cutillo G., Simon D.K., Eleuteri S. (2020) VPS35 and the mitochondria: connecting the dots in Parkinson’s disease pathophysiology. Neurobiol. Dis., 145, 105056. CrossRef Scholar google search
Olszewska D.A., McCarthy A., Lynch T. (2016) Commentary: Parkinson’s disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Front. Neurosci., 10, 162. CrossRef Scholar google search
Rowlands J., Moore D.J. (2024) VPS35 and retromer dysfunction in Parkinson’s disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 379, 20220384. CrossRef Scholar google search
Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19(14), 5782–5791. CrossRef Scholar google search
Tran H.L., Zheng W., Issadore D.A., Im H., Cho Y.-K., Zhang Y., Liu D., Liu Y., Li B., Liu F., Wong D.T.W., Sun J., Qian K., He M., Wan M., Zeng Y., Cheng K., Huang T.J., Chiu D.T., Lee L.P., Zheng L., Godwin A.K., Kalluri R., Soper S.A., Hu T.Y. (2025) Extracellular vesicles for clinical diagnostics: from bulk measurements to single-vesicle analysis. ACS Nano, 19(31), 28021–28109. CrossRef Scholar google search
Ryan B.J., Hoek S., Fon E.A., Wade-Martins R. (2015) Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease. Trends Biochem. Sci., 40(4), 200–210. CrossRef Scholar google search
Sohrabi T., Mirzaei-Behbahani B., Zadali R., Pirhaghi M., Morozova-Roche L.A., Meratan A.A. (2023) Common mechanisms underlying α-synuclein-induced mitochondrial dysfunction in Parkinson’s disease. J. Mol. Biol., 435(12), 167992. CrossRef Scholar google search
Guardia-Laguarta C., Area-Gomez E., Rüb C., Liu Y., Magrané J., Becker D., Voos W., Schon E.A., Przedborski S. (2014) α-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci., 34(1), 249–259. CrossRef Scholar google search
Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett., 486(3), 235–239. CrossRef Scholar google search
Reeve A.K., Ludtmann M.H., Angelova P.R., Simcox E.M., Horrocks M.H., Klenerman D., Gandhi S., Turnbull D.M., Abramov A.Y. (2015) Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis., 6(7), e1820. CrossRef Scholar google search
Erustes A.G., Guarache G.C., Guedes E.D.C., Leão A.H.F.F., Pereira G.J.D.S., Smaili S.S. (2022) α-Synuclein interactions in mitochondria-ER contacts: a possible role in Parkinson’s disease. Contact, 5, 25152564221119347. CrossRef Scholar google search
Geibl F.F., Henrich M.T., Xie Z., Zampese E., Ueda J., Tkatch T., Wokosin D.L., Nasiri E., Grotmann C.A., Dawson V.L., Dawson T.M., Chandel N.S., Oertel W.H., Surmeier D.J. (2024) α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease. Mol. Neurodegener., 19, 69. CrossRef Scholar google search
Shen L., Dettmer U. (2024) Alpha-synuclein effects on mitochondrial quality control in Parkinson’s disease. Biomolecules, 14(12), 1649. CrossRef Scholar google search
Ganjam G.K., Bolte K., Matschke L.A., Neitemeier S., Dolga A.M., Höllerhage M., Höglinger G.U., Adamczyk A., Decher N., Oertel W.H., Culmsee C. (2019) Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis., 10(11), 865. CrossRef Scholar google search
Liu Z., Shan S., Kang K., Wang S., Yong H., Sun Y., Bai Y., Song F. (2024) Mitochondrial transfer of α-synuclein mediates carbon disulfide-induced mitochondrial dysfunction and neurotoxicity. Ecotoxicol. Environ. Saf., 281, 116613. CrossRef Scholar google search
Vasquez V., Kodavati M., Mitra J., Vedula I., Hamilton D.J., Garruto R.M., Rao K.S., Hegde M.L. (2024) Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson’s disease and parkinsonism-dementia of Guam. Cell Death Dis., 15(12), 914. CrossRef Scholar google search
Gezen-Ak D., Yurttaş Z., Çamoǧlu T., Dursun E (2022) Could amyloid-β 1–42 or α-synuclein interact directly with mitochondrial DNA? A hypothesis. ACS Chemical Neurosci., 13(19), 2803–2812. CrossRef Scholar google search
Dhungel N., Eleuteri S., Li L.-B., Kramer N.J., Chartron J.W., Spencer B., Kosberg K., Fields J.A., Stafa K., Adame A., Lashuel H., Frydman J., Shen K., Masliah E., Gitler A.D. (2015) Parkinson’s disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron, 85(1), 76–87. CrossRef Scholar google search
Fu C., Yang N., Chuang J.-Z., Nakajima N., Iraha S., Roy N., Wu Z., Jiang Z., Otsu W., Radu R.A., Yang H.H., Lee M.P., Worgall T.S., Xiong W.-C., Sung C.-H. (2024) Mutant mice with rod-specific VPS35 deletion exhibit retinal α-synuclein pathology-associated degeneration. Nat. Commun., 15, 5970. CrossRef Scholar google search
Lu J., Wu M., Yue Z. (2020) Autophagy and Parkinson’s disease. Adv. Exp. Med. Biol., 1207, 21–51. CrossRef Scholar google search
Sironi L., Restelli L.M., Tolnay M., Neutzner A., Frank S. (2020) Dysregulated interorganellar crosstalk of mitochondria in the pathogenesis of Parkinson’s disease. Cells, 9(1), 233. CrossRef Scholar google search
Bono K., Hara-Miyauchi C., Sumi S., Oka H., Iguchi Y., Okano H.J. (2020) Endosomal dysfunction in iPSC-derived neural cells from Parkinson’s disease patients with VPS35 D620N. Mol. Brain, 13, 137. CrossRef Scholar google search
Tang F.-L., Erion J.R., Tian Y., Liu W., Yin D.-M., Ye J., Tang B., Mei L., Xiong W.-C. (2015) VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson’s disease. J. Neurosci., 35(29), 10613–10628. CrossRef Scholar google search
Miura E., Hasegawa T., Konno M., Suzuki M., Sugeno N., Fujikake N., Geisler S., Tabuchi M., Oshima R., Kikuchi A., Baba T., Wada K., Nagai Y., Takeda A., Aoki M. (2014) VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. Neurobiol. Dis., 71, 1–13. CrossRef Scholar google search
Chen X., Tsika E., Levine N., Moore D.J. (2023) VPS35 and α-synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease. Mol. Neurodegener., 18, 51. CrossRef Scholar google search
Niu M., Zhao F., Bondelid K., Siedlak S.L., Torres S., Fujioka H., Wang W., Liu J., Zhu X. (2021) VPS35 D620N knockin mice recapitulate cardinal features of Parkinson’s disease. Aging Cell, 20(5), e13347. CrossRef Scholar google search
Lin K.-J., Lin K.-L., Chen S.-D., Liou C.-W., Chuang Y.-C., Lin H.-Y., Lin T.-K. (2019) The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson’s disease. Int. J. Mol. Sci., 20(21), 5312. CrossRef Scholar google search
Pozo Devoto V.M., Falzone T.L. (2017) Mitochondrial dynamics in Parkinson’s disease: a role for α-synuclein? Dis. Model. Mech., 10(9), 1075–1087. CrossRef Scholar google search
Follett J., Bugarcic A., Yang Z., Ariotti N., Norwood S.J., Collins B.M., Parton R.G., Teasdale R.D. (2016) Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces α-synuclein aggregation. J. Biol. Chem., 291(35), 18283–18298. CrossRef Scholar google search
Persico M., Fang T.S.Z., Tucci C., Simon D., Eleuteri S. (2024) Investigating the indirect interaction between Vps35 and α-synuclein in Parkinson’s disease (S26.007). Neurology, 102(17 Supplement 1), DOI: 10.1212/WNL.0000000000204465. CrossRef Scholar google search
Villa N., Fraser C.S. (2024) Human eukaryotic initiation factor 4G directly binds the 40S ribosomal subunit to promote efficient translation. J. Biol. Chem., 300(5), 107242. CrossRef Scholar google search
Kim S.-H., Choi J.-H., Marsal-García L., Amiri M., Yanagiya A., Sonenberg N. (2023) The mRNA translation initiation factor eIF4G1 controls mitochondrial oxidative phosphorylation, axonal morphogenesis, and memory. Proc. Natl. Acad. Sci. USA, 120(25), e2300008120. CrossRef Scholar google search
Deng H., Gao K., Jankovic J. (2013) The VPS35 gene and Parkinson’s disease. Mov. Disord., 28(5), 569–575. CrossRef Scholar google search
Chartier-Harlin M.-C., Dachsel J.C., Vilariño-Güell C., Lincoln S.J., Leprêtre F., Hulihan M.M., Kachergus J., Milnerwood A.J., Tapia L., Song M.-S., le Rhun E., Mutez E., Larvor L., Duflot A., Vanbesien-Mailliot C., Kreisler A., Ross O.A., Nishioka K., Soto-Ortolaza A.I., Cobb S.A., Melrose H.L., Behrouz B., Keeling B.H., Bacon J.A., Hentati E., Williams L., Yanagiya A., Sonenberg N., Lockhart P.J., Zubair A.C., Uitti R.J., Aasly J.O., Krygowska-Wajs A., Opala G., Wszolek Z.K., Frigerio R., Maraganore D.M., Gosal D., Lynch T., Hutchinson M., Bentivoglio A.R., Valente E.M., Nichols W.C., Pankratz N., Foroud T., Gibson R.A., Hentati F., Dickson D.W., Destée A., Farrer M.J. (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet., 89(3), 398–406. CrossRef Scholar google search
Ando M., Fiesel F.C., Hudec R., Caulfield T.R., Ogaki K., Górka-Skoczylas P., Koziorowski D., Friedman A., Chen L., Dawson V.L., Dawson T.M., Bu G., Ross O.A., Wszolek Z.K., Springer W. (2017) The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol. Neurodegener., 12, 32. CrossRef Scholar google search
Trempe J.-F., Gehring K. (2023) Structural mechanisms of mitochondrial quality control mediated by PINK1 and Parkin. J. Mol. Biol., 435(12), 168090. CrossRef Scholar google search
Ge P., Dawson V.L., Dawson T.M. (2020) PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease. Mol. Neurodegener., 15, 20. CrossRef Scholar google search
König T., McBride H.M. (2024) Mitochondrial-derived vesicles in metabolism, disease, and aging. Cell Metab., 36(1), 21–35. CrossRef Scholar google search
Rakovic A., Grünewald A., Kottwitz J., Brüggemann N., Pramstaller P.P., Lohmann K., Klein C. (2011) Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts. PLOS One, 6(3), e16746. CrossRef Scholar google search
Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., Lu B. (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl. Acad. Sci. USA, 105(19), 7070–7075. CrossRef Scholar google search
Malik B.R., Godena V.K., Whitworth A.J. (2015) VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Hum. Mol. Genet., 24(21), 6106–6117. CrossRef Scholar google search
Williams E.T., Glauser L., Tsika E., Jiang H., Islam S., Moore D.J. (2018) Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. Hum. Mol. Genet., 27(18), 3189–3205. CrossRef Scholar google search
Martinez A., Lectez B., Ramirez J., Popp O., Sutherland J.D., Urbé S., Dittmar G., Clague M.J., Mayor U. (2017) Quantitative proteomic analysis of Parkin substrates in Drosophila neurons. Mol. Neurodegener., 12, 29. CrossRef Scholar google search
Ma K.Y., Fokkens M.R., Reggiori F., Mari M., Verbeek D.S. (2021) Parkinson’s disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy. Transl. Neurodegener., 10, 19. CrossRef Scholar google search
Бунеева О.А., Медведев А.Е. (2021) Белок DJ-1 и его роль в развитии болезни Паркинсона: исследования на экспериментальных моделях. Биохимия, 86(6), 771–786. CrossRef Scholar google search
Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der Brug M., Sandebring A., Miller D., Maric D., Cedazo-Minguez A., Cookson M.R. (2011) DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet., 20(1), 40–50. CrossRef Scholar google search
McCoy M.K., Cookson M.R. (2011) DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy, 7(5), 531–532. CrossRef Scholar google search
Skou L.D., Johansen S.K., Okarmus J., Meyer M. (2024) Pathogenesis of DJ-1/PARK7-mediated Parkinson’s disease. Cells, 13(4), 296. CrossRef Scholar google search
Imberechts D., Kinnart I.,Wauters F., Terbeek J., Manders L., Wierda K., Eggermont K., Madeiro R.F., Sue C., Verfaillie C., Vandenberghe W. (2022) DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. Brain, 145(12), 4368–4384. CrossRef Scholar google search
Wang Y., Dai X., Li H., Jiang H., Zhou J., Zhang S., Guo J., Shen L., Yang H., Lin J., Yan H. (2023) The role of mitochondrial dynamics in disease. MedComm, 4(6), e462. CrossRef Scholar google search
Zhang M., Li C., Ren J., Wang H., Yi F., Wu J., Tang Y. (2022) The double-faceted role of leucine-rich repeat kinase 2 in the immunopathogenesis of Parkinson’s disease. Front. Aging Neurosci., 14, 909303. CrossRef Scholar google search
Sandoval A., Corzo-López A., Duran P., Tovar-Soto D., Vargas-Caballero B., Galicia-Saldaña V., González-Ramírez R., Felix R. (2025) The leucine-rich repeat kinase 2 variant LRRK2G2019S up-regulates L-type (CaV1.3) calcium channel via the CaVβ3 subunit: possible role in the pathogenesis of Parkinson’s disease. Int. J. Mol. Sci., 26(7), 3229. CrossRef Scholar google search
Singh A., Zhi L., Zhang H. (2019) LRRK2 and mitochondria: recent advances and current views. Brain Res., 1702, 96–104. CrossRef Scholar google search
Buck S.A., Sanders L.H. (2025) LRRK2-mediated mitochondrial dysfunction in Parkinson’s disease. Biochem. J., 482(11), 721–739. CrossRef Scholar google search
Sosero Y.L., Gan-Or Z. (2023) LRRK2 and Parkinson’s disease: from genetics to targeted therapy. Ann. Clin. Transl. Neurol., 10(6), 850–864. CrossRef Scholar google search
West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA, 102(46), 16842–16847. CrossRef Scholar google search
Singh F., Ganley I.G. (2021) Parkinson’s disease and mitophagy: an emerging role for LRRK2. Biochem. Soc. Trans., 49(2), 551–562. CrossRef Scholar google search
Shafique A., Brughera M., Lualdi M., Alberio T. (2023) The role of Rab proteins in mitophagy: insights into neurodegenerative diseases. Int. J. Mol. Sci., 24(7), 6268. CrossRef Scholar google search
Fasiczka R., Naaldijk Y., Brahmia B., Hilfiker S. (2023) Insights into the cellular consequences of LRRK2-mediated Rab protein phosphorylation. Biochem. Soc. Trans., 51(2), 587–595. CrossRef Scholar google search
Mir R., Tonelli F., Lis P., Macartney T., Polinski N.K., Martinez T.N., Chou M.-Y., Howden A.J.M., König T., Hotzy C., Milenkovic I., Brücke T., Zimprich A., Sammler E., Alessi D.R. (2018) The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem. J., 475(11), 1861–1883. CrossRef Scholar google search
Pal P., Taylor M., Lam P.Y., Tonelli F., Hecht C.A., Lis P., Nirujogi R.S., Phung T.K., Dickie E.A., Wightman M., Macartney T., Pfeffer S.R., Alessi D.R. (2023) Parkinson’s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B. bioRxiv [Preprint], 2023.06.07.544051. CrossRef Scholar google search
Zhang H., Su Y., Qu Z., Zhang C., Ma S., Li X., Wang Y. (2024) Sonic hedgehog mediates high frequency-dependent deep brain stimulation for the correction of motor deficits in a Parkinson’s disease model. Neurosci. Bull., 40(11), 1732–1738. CrossRef Scholar google search
Esmaeli M., Dehabadi M.D., Ghanbari A., Yancheshmeh F.S.A. (2025) The role of Sonic hedgehog (SHH) in the formation of motor neurons and neurodegenerative diseases. Discov. Med., 2, 231. CrossRef Scholar google search
Gonzalez-Reyes L.E., Verbitsky M., Blesa J., Jackson-Lewis V., Paredes D., Tillack K., Phani S., Kramer E.R., Przedborski S., Kottmann A.H. (2012) Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron, 75(2), 306–319. CrossRef Scholar google search
Yao P.J., Manor U., Petralia R.S., Brose R.D., Wu R.T.Y., Ott C., Wang Y.-X., Charnoff A., Lippincott-Schwartz J., Mattson M.P. (2017) Sonic hedgehog pathway activation increases mitochondrial abundance and activity in hippocampal neurons. Mol. Biol. Cell, 28(3), 387–395. CrossRef Scholar google search
Dhekne H.S., Yanatori I., Gomez R.C., Tonelli F., Diez F., Schüle B., Steger M., Alessi D.R., Pfeffer S.R. (2018) A pathway for Parkinson’s disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. eLife, 7, e40202. CrossRef Scholar google search
Schmidt S., Luecken M.D., Trümbach D., Hembach S., Niedermeier K.M., Wenck N., Pflügler K., Stautner C., Böttcher A., Lickert H., Ramirez-Suastegui C., Ahmad R., Ziller M.J., Fitzgerald J.C., Ruf V., van de Berg W.D.J., Jonker A.J., Gasser T., Winner B., Winkler J., Vogt Weisenhorn D.M., Giesert F., Theis F.J., Wurst W. (2022) Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease. Nat. Commun., 13, 4819. CrossRef Scholar google search
Khan S.S., Jaimon E., Lin Y.-E., Nikoloff J., Tonelli F., Alessi D.R., Pfeffer S.R. (2024) Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson’s disease. Proc. Natl. Acad. Sci. USA, 121(132), e2402206121. CrossRef Scholar google search
Bae J.-E., Kang G.M., Min S.H., Jo D.S., Jung Y.-K., Kim K., Kim M.-S., Cho D.-H. (2019) Primary cilia mediate mitochondrial stress responses to promote dopamine neuron survival in a Parkinson’s disease model. Cell Death Dis., 10(12), 952. CrossRef Scholar google search
Bhardwaj K., Jha A., Roy A., Kumar H. (2024) The crucial role of VPS35 and SHH in Parkinson’s disease: understanding the mechanisms behind the neurodegenerative disorder. Brain Res., 1845, 149204. CrossRef Scholar google search
Bakhit Y., Tesson C., Ibrahim M.O., Eltom K., Eltazi I., Elsayed L.E.O., Lesage S., Seidi O., Corvol J., Wüllner U.; Sudanese Parkinson’s Disease Study Group (2023) PLA2G6-associated late-onset parkinsonism in a Sudanese family. Ann. Clin. Transl. Neurol., 10(6), 983–989. CrossRef Scholar google search
Ferese R., Scala S., Biagioni F., Giardina E., Zampatti S., Modugno N., Colonnese C., Storto M., Fornai F., Novelli G., Ruggieri S., Gambardella S. (2018) Heterozygous PLA2G6 mutation leads to iron accumulation within basal ganglia and Parkinson’s disease. Front. Neurol., 9, 536. CrossRef Scholar google search
Musthafa T., Nizami S.K., Mishra A., Hasan G., Gopurappilly R. (2025) Altered mitochondrial bioenergetics and calcium kinetics in young-onset PLA2G6 Parkinson’s disease IPSCS. J. Neurochem., 169, e70059. CrossRef Scholar google search
Liu J., Tan J., Tang B., Guo J. (2024) Unveiling the role of iPLA2β in neurodegeneration: from molecular mechanisms to advanced therapies. Pharmacol. Res., 202, 107114. CrossRef Scholar google search
Kinghorn K.J., Castillo-Quan J.I., Bartolome F., Angelova P.R., Li L., Pope S., Cochemé H.M., Khan S., Asghari S., Bhatia K.P., Hardy J., Abramov A.Y., Partridge L. (2015) Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain, 138(Pt 7), 1801–1816. CrossRef Scholar google search
Lin G., Lee P.-T., Chen K., Mao D., Tan K.L., Zuo Z., Lin W.-W., Wang L., Bellen H.J. (2018) Phospholipase PLA2G6, a parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to α-synuclein gain. Cell Metab., 28(4), 605–618.e6. CrossRef Scholar google search
Sargent D., Moore D.J. (2021) Mechanisms of VPS35- mediated neurodegeneration in Parkinson’s disease. Int. Rev. Mov. Disord., 2, 221–244. CrossRef Scholar google search
